Stayble Therapeutics AB publishes supplementary prospectus regarding the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.
NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB offentliggör tilläggsprospekt med anledning av företrädesemissionen”.
The Board of Directors of Stayble Therapeutics AB (”Stayble” or ”the Company”) has established a supplement (“the Supplementary Prospectus”) to the EU Growth Prospectus published on March 17th, 2023 (“the Prospectus”. The Supplementary Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.
The supplementary prospectus has been established after Stayble received additional pre-subscription commitments, a remuneration-free top-down underwriting commitment and an additional, not remuneration-free top-down underwriting commitment for the ongoing rights issue. The rights issue is thus covered up to approximately 90 percent (which equals approximately MSEK 31.7) of pre-subscription and underwriting commitments. Pre-subscription and underwriting commitments are not secured by advance transaction, bank guarantee or similar.
The Supplementary Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s (www.staybletherapeutics.com), Sedermera Corporate Finance AB’s (www.sedermera.se) and Nordic Issuing AB’s (www.nordic-issuing.se) respective web pages. The Supplementary Prospectus will also be made available on the web page of the Swedish Financial Supervisory Authority (www.fi.se).
Investors who before the announcement of the Supplementary Prospectus have registered or in other ways consented to buy or subscribe to the securities covered by the Prospectus are, according to article 23 of the Prospectus Regulation, entitled to recalling their registration or their consent within two days of the announcement of the Supplementary Prospectus, i. e. up to and including Match 31st, 2023.
Recalls are to be notified to Nordic Issuing AB, subject: Stayble Therapeutics, e-mail: info@nordic-issuing.se. The recall date considered is the date when the e-mail is received by Nordic Issuing AB. Investors who have subscribed to shares through trustees are to contact their trustees regarding recalls. Subscriptions that are not recalled will remain binding.
Advisors
In connection with the Rights Issue, Stayble has appointed Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent. Shark Communication AB has assisted the Company with advice regarding communication.
For more information
For more information about the Rights Issue, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: info@sedermera.se
For more information about Stayble, please contact:
Andreas Gerward, CEO Stayble Therapeutics AB
Phone: +46 (0) 730 808 397
E-mail: andreas.gerward@stayble.com
www.staybletherapeutics.com
About Stayble Therapeutics AB
Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. Aimed at patients who are not helped by physiotherapy and painkillers, the treatment is a single injection that is expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is currently conducting a Phase 2b clinical trial in DDD and a Phase 1b trial in LDH.
Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Advisor.
IMPORTANT INFORMATION
The information in this press release does not constitute an offer to sell or issue, or the solicitation of an offer to buy or acquire, or subscribe for, shares, subscription rights, paid subscribed share (“BTA”), warrants, newly issues shares or other securities in Stayble. Invitation to persons concerned to subscribe to shares will only be available through the EU Growth Prospectus which was published on March 17th 2023.
Neither shares, subscription rights, BTA, warrants, newly issued shares or other securities are recommended or approved by any American federal or state securities authority or supervisory authority. No shares, subscription rights, BTA, warrants, newly issues shares or other securities are registered or will be registered according to the United States Securities Act of 1933 in its current wording, or by any other admissible law in the United States, Australia, Japan, Canada, New Zeeland, South Africa, Hong Kong, Switzerland, Singapore, Russia, Belarus or any other country where the Rights Issue or distribution of this press release violates Swedish law or regulations or requires the a further prospectus to be drafted, registered or any other measures to be taken except those required by Swedish law. The press release, as well as the prospectus and other documents referring to the Rights Issue, are thus not permitted to distribute to or within any such jurisdiction.
This press release may contain forward-looking statements that reflect Stayble’s current view of future events as well as financial and operational development. Words such as “intend”, “assess”, “except”, “may”, “plan”, “estimate” and other expressions involving indications or predictions regarding future developments or trends, constitute forward-looking statements. Forward-looking statements by nature entail known as well as unknown risks and insecurities since they are dependent on future performance and circumstances. Forward-looking statements do not constitute any guarantee regarding future results or development and the actual results may significantly vary from what is stated in forward-looking statements.
This information, these opinions and these forward-looking statements found in this press release are only valid and this date and are subject to change without notice. Stayble makes no commitment to update or revise forward-looking statements, future events or similar circumstances except when required by applicable legislation.